180 related articles for article (PubMed ID: 17060381)
1. Impaired regulatory T-cell response and enhanced atherosclerosis in the absence of inducible costimulatory molecule.
Gotsman I; Grabie N; Gupta R; Dacosta R; MacConmara M; Lederer J; Sukhova G; Witztum JL; Sharpe AH; Lichtman AH
Circulation; 2006 Nov; 114(19):2047-55. PubMed ID: 17060381
[TBL] [Abstract][Full Text] [Related]
2. A functional role for inducible costimulator (ICOS) in atherosclerosis.
Afek A; Harats D; Roth A; Keren G; George J
Atherosclerosis; 2005 Nov; 183(1):57-63. PubMed ID: 15941568
[TBL] [Abstract][Full Text] [Related]
3. Differential CD28 and inducible costimulatory molecule signaling requirements for protective CD4+ T-cell-mediated immunity against genital tract Chlamydia trachomatis infection.
Marks E; Verolin M; Stensson A; Lycke N
Infect Immun; 2007 Sep; 75(9):4638-47. PubMed ID: 17635872
[TBL] [Abstract][Full Text] [Related]
4. Inducible costimulator (ICOS) is a marker for highly suppressive antigen-specific T cells sharing features of TH17/TH1 and regulatory T cells.
Vocanson M; Rozieres A; Hennino A; Poyet G; Gaillard V; Renaudineau S; Achachi A; Benetiere J; Kaiserlian D; Dubois B; Nicolas JF
J Allergy Clin Immunol; 2010 Aug; 126(2):280-9, 289.e1-7. PubMed ID: 20624644
[TBL] [Abstract][Full Text] [Related]
5. CD4+ICOS+ T lymphocytes inhibit T cell activation 'in vitro' and attenuate autoimmune encephalitis 'in vivo'.
Rojo JM; Pini E; Ojeda G; Bello R; Dong C; Flavell RA; Dianzani U; Portolés P
Int Immunol; 2008 Apr; 20(4):577-89. PubMed ID: 18310064
[TBL] [Abstract][Full Text] [Related]
6. Expression of ICOS on human melanoma-infiltrating CD4+CD25highFoxp3+ T regulatory cells: implications and impact on tumor-mediated immune suppression.
Strauss L; Bergmann C; Szczepanski MJ; Lang S; Kirkwood JM; Whiteside TL
J Immunol; 2008 Mar; 180(5):2967-80. PubMed ID: 18292519
[TBL] [Abstract][Full Text] [Related]
7. Constitutive GITR Activation Reduces Atherosclerosis by Promoting Regulatory CD4+ T-Cell Responses-Brief Report.
Meiler S; Smeets E; Winkels H; Shami A; Pascutti MF; Nolte MA; Beckers L; Weber C; Gerdes N; Lutgens E
Arterioscler Thromb Vasc Biol; 2016 Sep; 36(9):1748-52. PubMed ID: 27444204
[TBL] [Abstract][Full Text] [Related]
8. CD4⁺Foxp3⁺ Treg and its ICOS⁺ subsets in patients with myocardial infarction.
Ghourbani Gazar S; Andalib A; Hashemi M; Rezaei A
Iran J Immunol; 2012 Mar; 9(1):53-60. PubMed ID: 22426168
[TBL] [Abstract][Full Text] [Related]
9. Defective leptin/leptin receptor signaling improves regulatory T cell immune response and protects mice from atherosclerosis.
Taleb S; Herbin O; Ait-Oufella H; Verreth W; Gourdy P; Barateau V; Merval R; Esposito B; Clément K; Holvoet P; Tedgui A; Mallat Z
Arterioscler Thromb Vasc Biol; 2007 Dec; 27(12):2691-8. PubMed ID: 17690315
[TBL] [Abstract][Full Text] [Related]
10. Th1-Like ICOS+ Foxp3+ Treg Cells Preferentially Express CXCR3 and Home to β-Islets during Pre-Diabetes in BDC2.5 NOD Mice.
Kornete M; Mason ES; Girouard J; Lafferty EI; Qureshi S; Piccirillo CA
PLoS One; 2015; 10(5):e0126311. PubMed ID: 25946021
[TBL] [Abstract][Full Text] [Related]
11. ICOS controls the pool size of effector-memory and regulatory T cells.
Burmeister Y; Lischke T; Dahler AC; Mages HW; Lam KP; Coyle AJ; Kroczek RA; Hutloff A
J Immunol; 2008 Jan; 180(2):774-82. PubMed ID: 18178815
[TBL] [Abstract][Full Text] [Related]
12. ICOS mediates the generation and function of CD4+CD25+Foxp3+ regulatory T cells conveying respiratory tolerance.
Busse M; Krech M; Meyer-Bahlburg A; Hennig C; Hansen G
J Immunol; 2012 Aug; 189(4):1975-82. PubMed ID: 22815292
[TBL] [Abstract][Full Text] [Related]
13. ICOS mediates the development of insulin-dependent diabetes mellitus in nonobese diabetic mice.
Hawiger D; Tran E; Du W; Booth CJ; Wen L; Dong C; Flavell RA
J Immunol; 2008 Mar; 180(5):3140-7. PubMed ID: 18292537
[TBL] [Abstract][Full Text] [Related]
14. ICOS is essential for effective T-helper-cell responses.
Tafuri A; Shahinian A; Bladt F; Yoshinaga SK; Jordana M; Wakeham A; Boucher LM; Bouchard D; Chan VS; Duncan G; Odermatt B; Ho A; Itie A; Horan T; Whoriskey JS; Pawson T; Penninger JM; Ohashi PS; Mak TW
Nature; 2001 Jan; 409(6816):105-9. PubMed ID: 11343123
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive analysis of CD4+ T cells in the decision between tolerance and immunity in vivo reveals a pivotal role for ICOS.
Lischke T; Hegemann A; Gurka S; Vu Van D; Burmeister Y; Lam KP; Kershaw O; Mollenkopf HJ; Mages HW; Hutloff A; Kroczek RA
J Immunol; 2012 Jul; 189(1):234-44. PubMed ID: 22661090
[TBL] [Abstract][Full Text] [Related]
16. Atheroprotective effects of Alum are associated with capture of oxidized LDL antigens and activation of regulatory T cells.
Wigren M; Bengtsson D; Dunér P; Olofsson K; Björkbacka H; Bengtsson E; Fredrikson GN; Nilsson J
Circ Res; 2009 Jun; 104(12):e62-70. PubMed ID: 19478203
[TBL] [Abstract][Full Text] [Related]
17. ICOS-ligand expression on plasmacytoid dendritic cells supports breast cancer progression by promoting the accumulation of immunosuppressive CD4+ T cells.
Faget J; Bendriss-Vermare N; Gobert M; Durand I; Olive D; Biota C; Bachelot T; Treilleux I; Goddard-Leon S; Lavergne E; Chabaud S; Blay JY; Caux C; Ménétrier-Caux C
Cancer Res; 2012 Dec; 72(23):6130-41. PubMed ID: 23026134
[TBL] [Abstract][Full Text] [Related]
18. TSLPR deficiency attenuates atherosclerotic lesion development associated with the inhibition of TH17 cells and the promotion of regulator T cells in ApoE-deficient mice.
Wu C; He S; Peng Y; Kushwaha KK; Lin J; Dong J; Wang B; Lin J; Shan S; Liu J; Huang K; Li D
J Mol Cell Cardiol; 2014 Nov; 76():33-45. PubMed ID: 25117469
[TBL] [Abstract][Full Text] [Related]
19. ICOS Promotes the Function of CD4+ Effector T Cells during Anti-OX40-Mediated Tumor Rejection.
Metzger TC; Long H; Potluri S; Pertel T; Bailey-Bucktrout SL; Lin JC; Fu T; Sharma P; Allison JP; Feldman RM
Cancer Res; 2016 Jul; 76(13):3684-9. PubMed ID: 27197182
[TBL] [Abstract][Full Text] [Related]
20. ICOS controls Foxp3(+) regulatory T-cell expansion, maintenance and IL-10 production during helminth infection.
Redpath SA; van der Werf N; Cervera AM; MacDonald AS; Gray D; Maizels RM; Taylor MD
Eur J Immunol; 2013 Mar; 43(3):705-15. PubMed ID: 23319295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
